Since this is well in line with previous studies attesting similar effects to MAPK pathway inhibition with BRAF and MEK inhibitors [45–48], RSK seems to be an important mediator of the MAPK pathway induced immune evasive tumor state. The gene discussed is RPS6KA1; the disease is neoplasm.